|
 |
Factor VIIaThis page contains recent news articles, when available, and an overview of Factor VIIa but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The hope is that the artificial platelets can replace or augment the activity of the currently used clotting medication, known as factor VIIa, ... BusinessWeek Researchers develop synthetic platelets that stop bleeding twice as fast - Dec 21, 2009 ...and trump the results of other treatments, including recombinant factor VIIa, which is used clinically for uncontrolled bleeding. ... SmartPlanet.com (blog) 합성 혈소íŒ?, 지혈 시간 단축 효과 ë³´ì—¬ - Dec 16, 2009 ...얼마가 ë?” 걸릴지 알수 없지만 현재 í†µì œë¶ˆëŠ¥ì?˜ 출혈ì?„ 막기 위해 사용ë?˜ëŠ” 7a 혈액ì?‘ê³ ì?¸ìž?(recombinant factor VIIa)보다 25% ë?” ë¹ ë¥¸ 효과를 ë³´ì?¸ë‹¤ê³ ë§?했다. ... 데일리팜 Investigadores criam plaquetas sintéticas - Dec 17, 2009 São, de facto, mais eficazes a deter hemorragias do que o fármaco utilizado actualmente para acelerar a coagulação, o factor VIIa recombinante. ... Ciência Hoje Crean glóbulos rojos sintéticos y plaquetas que cicatrizan más - Dec 17, 2009 Las plaquetas artificiales tuvieron también un rendimiento mejor que el factor VIIa, utilizado para controlar el sangrado en quirófanos. w. Clarín.com Desarrollan plaquetas sintéticas que cortan antes las hemorragias - Dec 17, 2009 ...eran mucho más eficaces deteniendo la hemorragia que el fármaco utilizado en la actualidad para acelerar la coagulación, el factor VIIa recombinante. ... ADN.es Maxygen to buy back 6.6M shares - Nov 13, 2009 ...a vaccine discovery program and a potential $30 million milestone payment from Bayer HealthCare for its Factor VIIa hemophilia treatment. ... San Jose Business Journal GTC slashes workforce as cash reserves dwindle - Nov 9, 2009 ..."Moving forward, we are focusing on our key programs, ATryn and Factor VIIa. We will progress our other portfolio programs as we have partnering revenues to ... FierceBiotech GTC Biotherapeutics Reports Third Quarter 2009 Financial Results - Nov 6, 2009 ..."Moving forward, we are focusing on our key programs, ATryn ® and Factor VIIa. We will progress our other portfolio programs as we have partnering revenues ... WELT ONLINE Modern insulins drive up Novo Nordisk earnings - Oct 29, 2009 Among the major products in Novo's biopharmaceuticals business, sales of which climbed 10% to 3.25 billion kroner, NovoSeven (recombinant Factor VIIa) was ... Pharma Times GTC Raises $10M from LFB Biotech - Nov 2, 2009 ...to reduce expenses by $5 million to $6 million in 2010, focusing resources on its recombinant human antithrombin (ATryn) and Factor VIIa products. ... Xconomy Pathogen-Independent Approach Nets Pulmatrix $30M in Series B - Nov 2, 2009 The company also plans to reduce expenses by focusing on its ATryn and Factor VIIa programs. Shares of GTC (NASDAQ:GTCB) closed at $1.21 Monday, ... Therapeutics Daily (press release) (registration) Anticoagulant Therapy Increases Risk of Death After Haemorrhagic Stroke ... - Oct 20, 2009 After receiving fresh frozen plasma, vitamin K, and/or recombinant factor VIIa, the median INR subsequent to reversal therapy decreased to 1.25 (range, ... DG News money briefs - Nov 7, 2009 The job cuts and a decision to focus work on ATryn and Factor VIIa programs should save $5 million to $6 million in annualized expenses, ... Worcester Telegram Factor VIIa (Systemic). - Feb 1, 2006 Other commonly used names are coagulation factor VIIa (recombinant), eptacog alfa, factor 7, proconvertin, recombinant activated factor VIIa, ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Protocol for Factor VIIa Reduces Costs, Increases Off-Label Use - Feb 21, 2007 February 21, 2007 (Orlando) — Guidelines devised and implemented at the University of Michigan Health System in Ann Arbor for the appropriate use of ... Medscape Factor VIIa (Systemic).(Drug overview) - Aug 1, 2006 Other commonly used names are coagulation factor VIIa (recombinant), eptacog alfa, factor 7, proconvertin, recombinant activated factor VIIa, ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com … Maxygen to Co-Develop Recombinant Factor VIIa Therapeutics for... - Dec 15, 2005 Today, recombinant factor VIIa is approved in the United States and Europe for ... Analysts estimate that worldwide sales of all factor VIIa products could ... RedOrbit FDA OKs new coagulation formulation - May 12, 2008 NovoSeven RT -- the new formulation of NovoSeven Coagulation Factor VIIa ... NovoSeven RT and NovoSeven Coagulation Factor VIIa are manufactured by Novo ... United Press International Novo Nordisk starts Phase I trial of long-acting version of NovoSeven - Jun 15, 2007 COPENHAGEN (Thomson Financial) - Novo Nordisk AS said it has initiated a phase 1 clinical trial of GlycoPEGylated factor VIIa, a long-acting version of the ... Forbes Factor VIIa Safe, Effective in Management of Hard-to-Control Bleeding - Jan 11, 2006 Jan. 11, 2006 (San Francisco) -- A number of trials presented here this week at the 35th Critical Care Congress of the Society of Critical Care Medicine ... Medscape Novo Nordisk Changes Labeling for NovoSeven Coagulation Factor VIIa (... - Dec 2, 2005 ...the medical community about the addition of new Warnings and Adverse Reactions to the labeling for NovoSeven® Coagulation Factor VIIa (Recombinant). ... DG News … Drug Development Candidate in Factor VIIa Program for Hemophilia. - - May 6, 2008 Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … Presentation of Positive Preclinical Data on GlycoPEGylated Factor... - Jul 11, 2007 GlycoPEGylated Factor VIIa, currently in Phase I, is being developed by Novo Nordisk A/S under a license from Neose. ... Free with registration - M2 Presswire - AccessMyLibrary.com Neose Receives Milestone Payment From Novo Nordisk on Factor VIIa … - Nov 27, 2006 ...license agreement entered into November 2003 for the use of Neose's GlycoPEGylation(TM) technology to develop a next-generation version of Factor VIIa. ... Genetic Engineering News - Genetic Engineering News (press release) … Drug Development Candidate in Factor VIIa Program for Hemophilia - May 6, 2008 ..."Patients receiving factor VIIa therapy typically require multiple doses of ... These patients are then treated with factor VIIa, a protease enzyme that can ... RedOrbit … Results for NovoSeven Coagulation Factor VIIa (Recombinant) in... - Feb 24, 2005 NovoSeven Coagulation Factor VIIa (Recombinant) is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor ... DG News Press Release: Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates... - Apr 16, 2008 Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … in Alliance with Roche for Factor VIIa Therapeutics. - PR Newswire... - May 9, 2006 Maxygen Achieves Milestone in Alliance with Roche for Factor VIIa Therapeutics. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Use of recombinant factor VIIa for emergency reversal of anticoagulati... - Jan 1, 2007 Context: There is limited data regarding the use of activated recombinant factor VII (rFVIIa) in anticoagulated patients requiring reversal. ... Free with registration - Journal of Postgraduate Medicine - AccessMyLibrary.com Recombinant Human Coagulation Factor VIIa in Jehovah's Witness … - Apr 1, 2005 Indisputably, liver transplantation is among the most technically challenging operations in current practice and is compounded by significant coagulopathy ... RedOrbit Maxygen Receives Approval for Clinical Trial of Factor VIIa in the... - Jun 11, 2008 Maxygen, Inc. (Nasdaq:MAXY) today announced that it has filed a Clinical Trial Authorization (CTA) and received the necessary approvals in the United ... Genetic Engineering News - Genetic Engineering News (press release) … Announces Presentation of GlycoPEGylated Factor VIIa Data at the … - Dec 12, 2007 HORSHAM, Pa. -- Neose Technologies, Inc. (Nasdaq GM:NTEC) announced that two posters were presented regarding preclinical data for GlycoPEGylated ... Free with registration - Business Wire - AccessMyLibrary.com Prophylactic Factor VIIa Improves Quality of Life for Hemophiliacs: … - Dec 11, 2006 By Ric Susman. ORLANDO, FL -- December 11, 2006 -- Once daily administration of recombinant human coagulation factor VIIa as secondary prophylaxis against ... DG News … Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI... - Nov 25, 2008 Activation of Factor VII (Factor VIIa) by TF also leads tothe high incidence of thromboembolic complications seen in cancer patients. ... International Business Times … , Novo Nordisk Announce Preclinical Data on GlycoPEGylated Factor... - Jul 12, 2007 GlycoPEGylated Factor VIIa, currently in Phase I, is being developed by Novo Nordisk under a license from Neose, the companies said. FDA news - FDA news (subscription) … Development; P3 and P4 moieties analyzed, novel binding of factor... - Mar 21, 2005 ..."Selective factor VIIa-tissue factor complex (FVIIa/TF) inhibition is seen as a promising target for developing new anticoagulant drugs," wrote S. Kadono ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones Maxygen Achieves Milestone in Alliance with Roche for Factor VIIa … - May 9, 2006 Currently, recombinant factor VIIa is approved in the United States and ... The market for the use of all factor VIIa products for the treatment of new ... $4.95 - PR Newswire - ECNext Recombinant Factor VIIa May Be Effective for Acute-Onset ICH - Feb 23, 2005 Feb. 23, 2005 -- Recombinant factor VIIa (rFVIIa) may be effective for treating patients with acute-onset intracerebral hemorrhage, according to the results ... Medscape … (R) RT (Coagulation Factor VIIa [Recombinant] Room Temperat - May 13, 2008 FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors. from PR ... Pay-Per-View - PR Newswire - HighBeam Research Recombinant Factor VIIa and Thromboembolic Events - Jul 5, 2006 To the Editor: Dr O'Connell and colleagues 1 reviewed thromboembolic complications of recombinant human coagulation factor VIIa (rFVIIa) as reported to the ... Journal of American Medical Association - Journal of American Medical Association... … Who Receive Recombinant Activated Factor VIIa Show Lower Mortality:... - Jul 11, 2007 ..."We have seen some data indicating the possible efficacy of the off-label use of recombinant activated Factor VIIa in this kind of medical situation, ... DG News … Development; P3 and P4 moieties analyzed, novel binding of factor... - Mar 24, 2005 ..."Selective factor VIIa-tissue factor complex (FVIIa/TF) inhibition is seen as a promising target for developing new anticoagulant drugs," wrote S. Kadono ... Pay-Per-View - Blood Weekly - Factiva, from Dow Jones Recombinant activated factor seven in acute life-threatening bleeding... - Jan 30, 2006 Factor VIIa binds to TF in the presence of endothelial damage. The Factor VIIa/TF complex activates factor X (FXa), which in turn leads to a formation of ... Nature.com Recombinant factor VIIa for severe gastrointestinal hemorrhage … - Jun 1, 2007 Crohn disease (CD) may be responsible for life-threatening gastrointestinal (GI) bleeding, and the management of severe GI bleeding in CD is a therapeutic ... $4.95 - Southern Medical Journal - ECNext Press Release: Pharmacyclics Realigns to Focus on Advancing … - Feb 28, 2008 PCI-27483 is a small-molecule inhibitor of Factor VIIa expected to enter clinical ... PCI-27483 selectively inhibits Factor VIIa when it is complexed with a ... Pay-Per-View - PR Newswire - HighBeam Research GTC Biotherapeutics, Inc. Conference Call - Part 1. - Oct 2, 2006 I wan to begin this call by making a few comments regarding the strategic elements of our collaboration and the initial factor VIIa product. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … Two Abstracts on GlycoPEGylated Factor VIIa Accepted for the XXI … - Apr 20, 2007 ...relating to GlycoPEGylated recombinant Factor VIIa have been accepted for poster presentations at the XXIst Congress of the International Society on ... Genetic Engineering News - Genetic Engineering News (press release) Coagulation; Factor VIIa studied, dimerization-mediated activity … - Jun 27, 2005 2005 JUN 27 - (NewsRx.com) -- A study from the United States has documented the large enhancement of functional activity of active site-inhibited factor ... Pay-Per-View - Hematology Week - Factiva, from Dow Jones Press Release: Pharmacyclics Reports Third Quarter 2008 Financial … - Apr 24, 2008 Roche to co-develop next-generation factor VIIa therapeutics. ... Article: Raising factor VIIa affinity improves effects of ... Drug Week; March 29, ... Pay-Per-View - PR Newswire - HighBeam Research … ; Maxygen achieves milestone in alliance with Roche for factor VIIa... - Jun 7, 2006 Currently, recombinant factor VIIa is approved in the United States and ... The market for the use of all factor VIIa products for the treatment of new ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Recombinant Factor VIIa Does Not Reduce Risk of Death or Disability... - May 31, 2007 By Rachel Tilley. GLASGOW, UK – May 31, 2007 -- Recombinant factor VIIa (rFVIIa) did not reduce the incidence of death or severe disability in patients with ... DG News Press Release: Pharmacyclics Reports Fourth Quarter and Fiscal 2008 … - Aug 14, 2008 Roche to co-develop next-generation factor VIIa therapeutics. ... Article: Raising factor VIIa affinity improves effects of ... Drug Week; March 29, ... Pay-Per-View - PR Newswire - HighBeam Research Maxygen, Roche enter $95m Factor VIIa deal.(Friday, Dec. 16) - Dec 19, 2005 The widely accepted biotech rule for partnering is: Hold onto programs for as long as possible to build value. But that's not the way Maxygen Inc., ... Pay-Per-View - BioWorld Week - Factiva, from Dow Jones Press Release: Pharmacyclics Reports First Quarter 2008 Financial … - Oct 25, 2007 Roche to co-develop next-generation factor VIIa therapeutics. ... Article: Raising factor VIIa affinity improves effects of ... Drug Week; March 29, ... Pay-Per-View - PR Newswire - HighBeam Research … Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI... - Nov 25, 2008 The Factor VIIa: tissue factor complex, the pharmacologic target of PCI-27483, ... PCI-27483 selectively inhibits Factor VIIa when it is complexed ... ... Pay-Per-View - PR Newswire - HighBeam Research Potential use of recombinant factor VIIa on the battlefield?(Novo... - Mar 21, 2005 Denmark-based Novo Nordisk's recombinant factor VIIa, a blood-clotting agent developed for the treatment of hemophilia, is being considered by the UK ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones … Events After Use of Recombinant Human Coagulation Factor VIIa - Jan 18, 2006 Context The US Food and Drug Administration (FDA) licensed recombinant human coagulation factor VIIa (rFVIIa) on March 25, 1999, for bleeding in patients ... Journal of American Medical Association - Journal of American Medical Association... Press Release: FDA approves new formulation of Coagulation Therapy … - May 12, 2008 Roche to co-develop next-generation factor VIIa therapeutics. ... Article: Raising factor VIIa affinity improves effects of ... Drug Week; March 29, ... Pay-Per-View - M2 Presswire - HighBeam Research Outcome of alveolar hemorrhage in hematopoietic stem cell transplant ... - May 7, 2007 30, 31 We also studied the outcomes of patients who received factor VIIa for AH ... Recombinant factor VIIa was administered to 24 (28%) of the 87 patients ... Nature.com NEJM Publishes Promising Study of NovoSeven Coagulation Factor VIIa - Feb 28, 2005 Novo Nordisk has announced the results of a recently completed clinical trial of NovoSeven Coagulation Factor VIIa (recombinant) in patients with acute ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Custom ligand for purifying recombinant VIIa - May 30, 2008 LFB and GTC are producing Factor VIIa in the milk of animals that express this recombinant protein during lactation. BAC has a proven reputation for the ... Laboratory Talk Gene Expression; Factor VIIa binding causes differential gene... - Jan 9, 2006 2006 JAN 9 - (NewsRx.com) -- Research from Germany has reported on differential gene expression in activated monocyte-derived macrophages following binding ... Pay-Per-View - Hematology Week - Factiva, from Dow Jones … Data Presentations on GlycoPEGylated Factor VIIa at the American … - Nov 20, 2007 GlycoPEGylated Factor VIIa is being developed by Novo Nordisk under a license agreement with Neose and is currently in Phase I. ... $4.95 - Business Wire - ECNext Article: Recombinant Factor C assay.(in vitro diagnostic components:... - May 1, 2005 Article: Recombinant Factor VIIa Decreases Transfusion ... ... Orthotopic Liver Transplantation Due to Recombinant Factor VIIA (RFVIIA, Novoseven ... ... Pay-Per-View - Medical Device Technology - HighBeam Research Bloomberg Printer-Friendly Page - May 27, 2008 Recombinant Factor VIIa is used in the treatment of bleeding episodes and for the ... The worldwide market for recombinant Factor VIIa was approximately $1 ... Bloomberg Gene Expression; Factor VIIa binding causes differential gene... - Jan 12, 2006 2006 JAN 12 - (NewsRx.com) -- Research from Germany has reported on differential gene expression in activated monocyte-derived macrophages following binding ... Pay-Per-View - Blood Weekly - Factiva, from Dow Jones DDW: For Variceal Bleeding, Clotting Factor Is Not First-Line Therapy - May 20, 2007 WASHINGTON, May 20 -- Recombinant clotting Factor VIIa should be used only as a ... Note that this trial tested the use of clotting Factor VIIa in variceal ... MedPage Today Adverse Drug Reaction; Human coagulation factor VIIa therapy is... - Mar 16, 2006 2006 MAR 16 - (NewsRx.com) -- Thromboembolic adverse events were more likely after recombinant human coagulation factor VIIa therapy for unlabeled uses. ... Pay-Per-View - Blood Weekly - Factiva, from Dow Jones … Nordisk's NovoSeven RT (Coagulation Factor VIIa [Recombinant]) is... - Jun 16, 2008 Novo Nordisk's NovoSeven RT (Coagulation Factor VIIa [Recombinant]) is a room-temperature stable recombinant drug for the treatment of bleeding episodes in ... $9.94 - Drug Topics - Alacra Store Adverse Drug Reaction; Human coagulation factor VIIa therapy is... - Mar 19, 2006 2006 MAR 19 - (NewsRx.com) -- Thromboembolic adverse events were more likely after recombinant human coagulation factor VIIa therapy for unlabeled uses. ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Adverse Drug Reaction; Human coagulation factor VIIa therapy is... - Mar 13, 2006 2006 MAR 13 - (NewsRx.com) -- Thromboembolic adverse events were more likely after recombinant human coagulation factor VIIa therapy for unlabeled uses. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones … of Initial Phase 1 Clinical Trial of NN7128 (Long-Acting Factor... - Jun 2, 2008 Recombinant Factor VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients ... Genetic Engineering News - Genetic Engineering News (press release) EPTACOG ALFA (Intravenous route) - koh-a-gyoo-LAY-shun FAK-tor SEV … - May 1, 2007 Factor VIIa is a man-made protein produced to replicate the naturally occurring ... Factor VIIa is used to stop bleeding of injuries for patients with ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Cardiology; Recombinant factor VIIa use in cardiac surgery produces... - Oct 3, 2006 2006 OCT 3 - (NewsRx.com) -- Recent research from Canada has reported on determinants of complications with recombinant factor VIIa (rFVIIa) for refractory ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Recombinant Factor VIIa and Thromboembolic Events—Reply - Jul 5, 2006 In Reply: The comments from Dr Dutton and colleagues emphasize the importance of benefit-risk considerations for patients in extremis vs those who are not. ... Journal of American Medical Association - Journal of American Medical Association... Danish shares close higher, led up by AP Moller-Maersk stocks, Genmab... - Jun 15, 2007 The group has started a phase 1 clinical trial of GlycoPEGylated factor VIIa, a long-acting version of its NovoSeven Coagulation Factor VIIa (recombinant), ... Forbes Recombinant factor VIIa for severe gastrointestinal hemorrhage … - Jun 1, 2007 Recombinant factor VIIa for severe gastrointestinal hemorrhage associated with Crohn disease.(Editorial) ... find Southern Medical Journal articles. Pay-Per-View - Southern Medical Journal - HighBeam Research Drugs that stop bleeding in the brain - Sep 1, 2008 Safety and Feasibility of recombinant Factor VIIa for acute intracerebral haemorrhage. Stroke. 2005; 36: 74-79. Mayer SA, Brun NC, Begtrup K, et al. ... guardian.co.uk Waging war on death - Jul 5, 2008 Known as recombinant Factor VIIa, the medication is approved in Canada and the ... Finally, surgeons administered Factor VIIa and "within one minute" the ... National Post Bloomberg Printer-Friendly Page - May 19, 2008 A Phase I trial of GlycoPEG-Factor VIIa is currently ongoing. "We are excited about Novo Nordisk's continued progress in developing a long-acting Factor IX ... Bloomberg Cutting-Edge Trauma Surgery -- What's Proven, What's Not? - Feb 1, 2005 Contrary to popular belief, Dr. Scalea said, factor VIIa does not "clot off ... [13] Emerging data from Europe suggest that even though factor VIIa did ... Medscape GTC Biotherapeutics Reports Third Quarter 2006 Financial Results. - Nov 2, 2006 Factor VIIa is used for those hemophiliacs who have developed inhibitors, or antibodies, to other coagulation factors. * This is a large market opportunity ... Free with registration - Business Wire - AccessMyLibrary.com Boundaries tested out of necessity - Mar 27, 2006 The war experience with Recombinant Factor VIIa could provide valuable data for the home front about an expensive medicine, says Richard Dutton, ... Pay-Per-View - USA TODAY - ProQuest Archiver LFB and GTC to Collaborate on Recombinant Plasma Proteins - May 8, 2008 In addition to the recombinant alpha-1 antitrypsin program, the GTC/LFB Biotechnologies collaboration includes recombinant factor VIIa, recombinant factor ... RedOrbit Less Hemorrhaging After Stroke, But Not Fewer Deaths: Pharmaceutical ... - Jun 14, 2008 The new study compares the effectiveness of factor VIIa in two dosages (20 and ... However, patients who were treated with the higher dosage of factor VIIa ... Medical News Today - Medical News Today (press release) Successful treatment of severe gastrointestinal bleeding secondary to... - Jun 1, 2007 In this case, the use of recombinant activated factor VIIa controlled the ... Article: Recombinant factor VIIa for severe gastrointestinal hemorrhage ... ... Pay-Per-View - Southern Medical Journal - HighBeam Research Pharmaceutical study: Less hemorrhaging after stroke, but not fewer … - Jun 11, 2008 The new study compares the effectiveness of factor VIIa in two dosages (20 and ... However, patients who were treated with the higher dosage of factor VIIa ... Genetic Engineering News - Genetic Engineering News (press release) … Presentation of Positive Preclinical Data on GlycoPEGylated Factor... - Jul 11, 2007 GlycoPEGylated Factor VIIa, currently in Phase I, is being developed by Novo ... LFB Biotechnologies to Develop Recombinant Forms of Human Factor VIIa and ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Pharmacyclics Inc. Review in Progress. - M2 Presswire... - Apr 24, 2008 Positive Preclinical Data on GlycoPEGylated Factor VIIa(C)1994-2007 M2 ... GlycoPEGylated Factor VIIa, currently in Phase I, is being developed ... ... Pay-Per-View - M2 Presswire - HighBeam Research Article: NSW: Doctors hail "wonder drug" for helping to save Sophie -... - May 6, 2006 FDA Approves Supplemental Use of NovoSeven(R) Coagulation Factor VIIa ... Food and Drug Administration to market NovoSeven Coagulation Factor VIIa ... Pay-Per-View - AAP General News - HighBeam Research Is use of these agents justified? Here are tips. - Nov 21, 2005 Most hospitals should also avoid routine use of recombinant Factor VIIa, indicated to control ... "We found Factor VIIa being used in almost every unit. ... $9.94 - Drug Topics - Alacra Store BAYER EXPANDS HEMOPHILIA PORTFOLIO FEATURING MAXY-VII. - Aug 1, 2008 In these instances a Factor VIIa is used to bypass inhibitors and help these ... MAXY-VII is a next generation Factor VIIa clotting factor that may offer an ... Entrepreneur Acquired hemophilia A presenting post partum.(Teaching Case Report)( … - Aug 14, 2007 Recombinant activated factor VIIa concentrate (90 [micro]g/kg [4.8 mg]) was given ... Activated coagulation factors (recombinant activated factor VIIa and ... Free with registration - CMAJ: Canadian Medical Association... - AccessMyLibrary.com First potential treatment for intracerebral hemorrhage - Jan 18, 2006 She hopes NovoSeven®, or recombinant activated factor VIIa, will. Activated factor VIIa is a substance certain hemophilia patients may not have enough of. ... News-Medical.net Potential Treatment For Intracerebral Hemorrhage Under Study - Jan 20, 2006 She hopes NovoSeven®, or recombinant activated factor VIIa, will. Activated factor VIIa is a substance certain hemophilia patients may not have enough of. ... sciencedaily.com Q2 2007 Maxygen, Inc. Earnings Conference Call - Final. - Aug 2, 2007 Currently there's only one Factor VIIA gross product on the market. ... Nova VII is a recombinant form of wild type factor VIIa, sales of this drug in 2006 ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Potential Treatment For Intracerebral Hemorrhage Under Study - Feb 3, 2006 She hopes NovoSeven, or recombinant activated factor VIIa, will. Activated factor VIIa is a substance certain hemophilia patients may not have enough of. ... 生物谷 Press Release: Nuvelo Announces Published Abstracts and … - Oct 19, 2006 Novel Tissue Factor/Factor VIIa Inhibitor Reduces Ischemia in Patients with ... Patients with ACS are currently ... complex Factor VIIa/Tissue Factor, ... Pay-Per-View - PR Newswire - HighBeam Research Nuvelo Announces Publication Of Phase 2 RNAPc2 Study Results In … - Jun 20, 2007 In animal models, the tissue factor/factor VIIa protease complex has been shown to play a role in activating the cellular signaling events leading to ... Medical News Today - Medical News Today (press release) Nuvelo BEGINS Phase 2 'Proof of Concept' Trial Evaluating rNAPc2 in … - Aug 22, 2005 The poster presentation entitled, "Addition of a Tissue- Factor/Factor VIIa Inhibitor to Standard Treatments in NSTE-ACS Managed with an Early Invasive ... RedOrbit Nuvelo Initiates Phase 2 Trial of rNAPc2. - Jan 4, 2007 The factor VIIa/tissue factor protease complex has been shown to play a role in the cellular signaling of both metastasis and angiogenesis in a variety of ... Free with registration - M2 Presswire - AccessMyLibrary.com CSL Behring Study in Animal Models Shows Feasibility of Developing a ... - Dec 10, 2007 Recombinant factor VIIa (rFVIIa) may be used to control bleeding episodes in hemophilia patients with inhibitors. These patients develop an immune response ... Free with registration - PR Newswire - AccessMyLibrary.com Study Shows Feasibility Of Developing Half-Life Extended Recombinant ... - Dec 12, 2007 Recombinant factor VIIa (rFVIIa) may be used to control bleeding episodes in hemophilia patients with inhibitors. These patients develop an immune response ... emaxhealth.com Q1 2007 Nuvelo, Inc. Financial Results Conference Call - Final. - May 9, 2007 As you know, rNAPc2 blocks the factor VIIa/tissue factor protease complex, ... As rNAPc2 is an inhibitor of the tissue factor and factor VIIa interaction, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Drug Shows Promise For Treating Strokes - Feb 24, 2005 The drug, called Factor VIIa and approved for treatment of hemophilia, potentially could save the lives of thousands of stroke patients annually. ... Subscription - Wall Street Journal Online - Dow Jones & Company Novo Nordisk gets transparent on bioethics - Jul 5, 2007 Meanwhile, the company recently initiated a phase I clinical trial of GlycoPEGylated factor VIIa (recombinant), a long-acting version of its drug NovoSeven ... DrugResearcher.com Nuvelo Receives FDA Fast Track Status For RNAPc2 In Both First- And … - Mar 29, 2007 Recombinant nematode anticoagulant protein c2 (rNAPc2) is a recombinant protein that interferes with the tissue factor/factor VIIa/factor Xa protease ... Medical News Today - Medical News Today (press release) Bayer Buys Maxygen Hematology Drugs - Jul 11, 2008 MAXY-VII, a Factor VIIa protein and lead therapeutic candidate, is expected to ... In such instances, a Factor VIIa protein is used to bypass the antibodies ... FDA news - FDA news (subscription) FAST: rFVIIa has no effect on death or disability after ICH.(Meeting ... - Jul 1, 2007 Hemostatic treatment with recombinant activated factor vIIa (rFVIIa) failed to ... The results from the Factor VIIa for Acute Hemorrhagic Stroke Treatment ... Free with registration - Formulary - AccessMyLibrary.com Nuvelo Announces Final Results of Phase 2a Trial of rNAPc2 to be … - Nov 7, 2005 The poster presentation (abstract #2095/C16) entitled "Addition of a Tissue-Factor/Factor VIIa Inhibitor to Standard Treatments in NSTE-ACS Managed with an ... Free with registration - PR Newswire - AccessMyLibrary.com Nuvelo Announces Published Abstract and Presentation on rNAPc2 in … - Dec 6, 2006 Abstract # 904: rNAPc2, a Novel Inhibitor of Tissue Factor/Factor VIIa Complex, ... rNAPc2 blocks the factor VIIa/tissue factor protease complex, ... Free with registration - PR Newswire - AccessMyLibrary.com Abstract and Introduction - Jun 22, 2007 Recombinant factor VIIa as adjunctive therapy for bleeding control in ... Early use of recombinant factor VIIa improves mean arterial pressure and may ... Medscape Q1 2006 Maxygen, Inc. Earnings Conference Call - Final. - Apr 25, 2006 Lastly to our Factor VIIa codevelopment alliance with Roche. Maxygen is making good progress in our Factor VIIa program. This is a codevelopment alliance ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |